AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9247907
Drug: Troglitazone (investigational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troglitazone (investigational drug) with standard diet and exercise
Trial: 8290882
Drug: Miconazole chewing
RxNorm normalized name: Miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Miconazole chewing gum (3.6 mg, four times daily)
Trial: 8290882
Drug: Miconazole gel
RxNorm normalized name: Miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Miconazole gel (50 mg, four times daily)
Trial: 3326678
Drug: Buffered aspirin
RxNorm normalized name: Buffered Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Buffered aspirin 600 mg
Trial: 25516196
Drug: Metoclopramide 10
RxNorm normalized name: metoclopramide 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide 10 mg 3× daily via nasogastric tube for 21 days
Trial: 25516196
Drug: Placebo 3×
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 3× daily via nasogastric tube for 21 days
Trial: 22951068
Drug: Methadone maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone maintenance treatment (mean dose 95.7mg, SD 48.9)
Trial: 22951068
Drug: Higher methadone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher methadone dose
Trial: 22951068
Drug: Urine drug
RxNorm normalized name: Urin DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urine drug screening (UDS) positive for opiates, cocaine, and amphetamines
Trial: 19697301
Drug: Caffeine (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (administered in one double-blind group)
Trial: 14698135
Drug: Paclitaxel (weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel (weekly or every 3 weeks)
Trial: 14698135
Drug: Paclitaxel (weekly)
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel (weekly)
Trial: 12405649
Drug: Prebiotic mixture
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prebiotic mixture (6 g/d of a 70% raftilose and 30% raftiline mixture)
Trial: 12405649
Drug: Placebo (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (6 g of maltodextrin powder)
Trial: 9680679
Drug: Low inhibitory
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low inhibitory control conditions (e.g., misleading pictorial cues or arrows)
Trial: 8021037
Drug: 0.4% SnF2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4% SnF2 gel (n = 30) used twice daily for 18 months
Trial: 2681637
Drug: Recombinant somatropin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant somatropin, 0.1 mg/kg three times a week
Trial: 30270047
Drug: Oral acetaminophen
RxNorm normalized name: acetaminophen Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral acetaminophen administered within 1 hour of induction
Trial: 30270047
Drug: Oral acetaminophen
RxNorm normalized name: acetaminophen Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral acetaminophen (treatment group)
Trial: 29066159
Drug: n‐3 long‐chain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n‐3 long‐chain polyunsaturated fatty acids (LCPUFA) 4 g/d for three months
Trial: 26287149
Drug: Carboxymethyl-glucan (CM-G)
RxNorm normalized name: sodium carboxymethyl beta-glucan (DS 0.65-0.85)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboxymethyl-glucan (CM-G) administered orally for 60 days
Trial: 21429334
Drug: Specific immunotherapy
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific immunotherapy (n = 32)
Trial: 21429334
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment (n = 32)
Trial: 17407369
Drug: Lisdexamfetamine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisdexamfetamine (50 or 100 mg doses)
Trial: 15065981
Drug: Sequential lineup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential lineup with absolute height encoding
Trial: 11731354
Drug: Fluoxetine 10
RxNorm normalized name: fluoxetine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 10 mg daily for 1 week, then increased to 20 mg daily
Trial: 24622005
Drug: ASCEND-HF trial
RxNorm normalized name: Prascend
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASCEND-HF trial patients (Nesiritide treatment)
Trial: 24622005
Drug: Population-level cohorts
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Population-level cohorts (not specified treatment)
Trial: 16526312
Drug: Oral bicarbonate
RxNorm normalized name: sodium bicarbonate Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral bicarbonate therapy (1.2 mEq/kg of body weight daily)
Trial: 1750016
Drug: Nasal sprays
RxNorm normalized name: SODIUM CHLORIDE 9 mg in 100 mL INTRASINAL AEROSOL, SPRAY [Cleanote Saline Nasal Sprays]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal sprays of recombinant alpha 2 interferon (3 x 10(6) IU) twice daily for five days
Trial: 1750016
Drug: Placebo twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo twice daily for five days
Trial: 30820429
Drug: Incise drape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Incise drape (ID) used in treatment group
Trial: 20848500
Drug: Open-label adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Open-label adalimumab weekly therapy
Trial: 20848500
Drug: Open-label adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Open-label adalimumab EOW therapy
Trial: 20848500
Drug: Blinded adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Blinded adalimumab EOW therapy
Trial: 8660045
Drug: Ciprofloxacin (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (70 mg/kg given over 7 d)
Trial: 8660045
Drug: Ofloxacin (45‐50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin (45‐50 mg/kg given over 3‐5 d)
Trial: 6872416
Drug: Sublingual lorazepam
RxNorm normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual lorazepam 2 mg every 2 hr with supportive care (21 patients)
Trial: 6872416
Drug: Sublingual placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual placebo every 2 hr with supportive care (20 patients)
Trial: 6872416
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (21 drug group and 20 no-drug group)
Trial: 30703096
Drug: Mass deworming
RxNorm normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mass deworming treatment
Trial: 24755106
Drug: Problem-solving therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Problem-solving therapy (PST) for 6 weeks from a licensed renal social worker
Trial: 22318468
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 1,200 mg daily for 6 weeks
Trial: 22318468
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 2,400 mg daily for 6 weeks
Trial: 17448578
Drug: Killed oral
RxNorm normalized name: Hongo Killer
DrugBank: Undecylenic acid (DB11117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Killed oral vaccine for enterotoxigenic E. coli (ETEC) diarrhoea, two doses with colonization factor antigens (CF) and cholera B subunit
Trial: 12421104
Drug: Bicalutamide 150
RxNorm normalized name: bicalutamide 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bicalutamide 150 mg/day as an adjunct to radiotherapy, radical prostatectomy or watchful waiting
Trial: 12421104
Drug: Bicalutamide 150
RxNorm normalized name: bicalutamide 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bicalutamide 150 mg/day monotherapy
Trial: 9708750
Drug: Levonorgestrel (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levonorgestrel (0.75 mg, repeated 12 h later)
Trial: 9708750
Drug: Yuzpe regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yuzpe regimen (ethinyloestradiol 100 microg plus levonorgestrel 0.5 mg, repeated 12 h later)
Trial: 8567563
Drug: Graded epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Graded epinephrine infusion (0.02-0.12 micrograms.kg-1.min-1)
Trial: 8567563
Drug: Control test
RxNorm normalized name: CHEK-STIX URINALYSIS CONTROL TEST STRIP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control test (no epinephrine infusion)
Trial: 23865591
Drug: Hyoscine butylbromide
RxNorm normalized name: Hyoscine butylbromide
DrugBank: Butylscopolamine (DB09300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyoscine butylbromide (HBB) 20-100 mg/day
Trial: 16696804
Drug: mesalazine 2400
RxNorm normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: mesalazine 2400 mg/day
Trial: 18565598
Drug: Topical treatment
RxNorm normalized name: Hongo Killer Treatment Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical treatment (ear drops and saline solution)
Trial: 18565598
Drug: Topical treatment
RxNorm normalized name: Hongo Killer Treatment Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical treatment with systemic antibiotics
Trial: 10505732
Drug: Sucralfate enemas
RxNorm normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sucralfate enemas (20 g/100 ml)
Trial: 10505732
Drug: Methylprednisolone enemas
RxNorm normalized name: methylprednisolone acetate Enema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone enemas (20 mg/100 ml)
Trial: 6581065
Drug: Fenoterol powder
RxNorm normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoterol powder for inhalation
Trial: 6581065
Drug: Fenoterol spray
RxNorm normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoterol spray
Trial: 27681016
Drug: Interdental brushes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interdental brushes used daily with a standard manual toothbrush twice daily
Trial: 17507702
Drug: Continued fluticasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued fluticasone (100 microg twice daily)
Trial: 17507702
Drug: Montelukast (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast (5 or 10 mg each night)
Trial: 11552615
Drug: Ultrasound treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound treatment (10 procedures)
Trial: 11552615
Drug: Sonophoresis treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sonophoresis treatment (diclofenac gel, 10 procedures)
Trial: 7768254
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg ramipril orally
Trial: 7768254
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg ramipril intravenously
Trial: 7768254
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg ramiprilat intravenously
Trial: 2283645
Drug: Diltiazem (60-180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (60-180 mg twice daily)
Trial: 2283645
Drug: Captopril (25-75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (25-75 mg twice daily)
Trial: 31530665
Drug: continued GLP-1
RxNorm normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: continued GLP-1 RA therapy
Trial: 29978268
Drug: 940-nm diode
RxNorm normalized name: NM-004
DrugBank: NM-004 (DB18066)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 940-nm diode laser treatment after undisplaced flap surgery
Trial: 29978268
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (surgery without laser treatment)
Trial: 26429974
Drug: Discontinue ACEi,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinue ACEi, ARB or combination of both (experimental arm)
Trial: 26429974
Drug: Continue ACEi,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continue ACEi, ARB or combination of both (control arm)
Trial: 14643168
Drug: Ambroxol (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambroxol (75 mg twice daily)
Trial: 14643168
Drug: Ambroxol (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambroxol (75 mg twice daily) in patients with more severe symptoms
Trial: 8492965
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose methotrexate (7500 mg/m2)
Trial: 8492965
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose methotrexate (750 mg/m2)
Trial: 25908089
Drug: Stenting plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stenting plus best medical treatment
Trial: 23427864
Drug: metformin+pioglitazone combination
RxNorm normalized name: metformin / pioglitazone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metformin+pioglitazone combination
Trial: 19368145
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus Aloe arborescens (10 ml thrice daily)
Trial: 19368145
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus Aloe arborescens
Trial: 16442593
Drug: Paclitaxel (175
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel (175 mg/m2 every 3-week cycle) and carboplatin (area under the curve of 5 every 3-week cycle)
Trial: 16442593
Drug: Mitoxantrone (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitoxantrone (12 mg/m2 every 3-week cycle)
Trial: 11424018
Drug: Topical resiquimod
RxNorm normalized name: Resiquimod
DrugBank: Resiquimod (DB06530)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical resiquimod gel 0.01% (twice or thrice weekly) or 0.05% (once or twice weekly)
Trial: 8618466
Drug: Induction therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction therapy of varying intensities (specific details not provided)
Trial: 8618466
Drug: Induction treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction treatment (specific details not provided)
Trial: 1533542
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg kg‐1
Trial: 1533542
Drug: 12 mg
RxNorm normalized name: pectin 12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mg kg‐1
Trial: 1533542
Drug: 6 and
RxNorm normalized name: Plasma-Lyte 56 and 5% Dextrose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 and 12 mg kg‐1
Trial: 25156968
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (40 mg/d)
Trial: 25156968
Drug: Flaxseed oil
RxNorm normalized name: Flaxseed Oil
DrugBank: Linseed oil (DB11357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flaxseed oil supplementation (2 g/d)
Trial: 22192409
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of CPM and distraction
Trial: 20338728
Drug: Ketoprofen administered
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketoprofen administered 60 min preoperatively
Trial: 20338728
Drug: Ketoprofen administered
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketoprofen administered 60 min postoperatively
Trial: 18843872
Drug: Oral pilocarpine
RxNorm normalized name: Pilocarpine
DrugBank: Pilocarpine (DB01085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral pilocarpine (5 mg) 1-tablet three times daily for three months
Trial: 18843872
Drug: Placebo 1-tablet
RxNorm normalized name: PLACEBO TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 1-tablet three times daily for the first month
Trial: 3894551
Drug: Transdermal scopolamine
RxNorm normalized name: Transderm Scop
DrugBank: Scopolamine (DB00747)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal scopolamine medication (one active medication patch)
Trial: 30360970
Drug: Filgotinib 200
RxNorm normalized name: nilotinib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Filgotinib 200 mg orally once daily for 12 weeks
Trial: 30360970
Drug: Placebo orally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo orally once daily for 12 weeks
Trial: 23360100
Drug: 20 IU
RxNorm normalized name: Calcium/Phosphorus/Vitamin D 105 MG-81 MG-120 IU Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 IU AVP (administered nasally)
Trial: 23360100
Drug: Placebo (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (administered nasally)
Trial: 15305186
Drug: Capecitabine at
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine at 2000 mg m(‐2) day(‐1)
Trial: 15305186
Drug: Capecitabine at
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine at 1800 mg m(‐2) day(‐1)
Trial: 15305186
Drug: Capecitabine (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine (various dose levels)
Trial: 8400675
Drug: Indomethacin (IDM)
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indomethacin (IDM) 50 mg every 8 hours for 4 days
Trial: 8400675
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no IDM or other non-steroidal anti-inflammatory drug)
Trial: 29703528
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acid supplements (fish oil and flaxseed oil)
Trial: 26321018
Drug: Intranasal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal administration of arginine vasopressin 1A and 1B receptor agonist
Trial: 18341378
Drug: Amifostine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amifostine (300 mg/m2 intravenously before 131I administration)
Trial: 18341378
Drug: Dose of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose of 131I
Trial: 12213943
Drug: Reviparin (1750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reviparin (1750 anti-Xa units given once daily)
Trial: 7485128
Drug: L-carnitine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine (1 g intravenously after every dialysis session for 6 months)
Trial: 6988106
Drug: Flunisolide (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunisolide (200 micrograms total: 25 micrograms/actuation, 2 actuations into each nostril twice a day)
Trial: 25880498
Drug: Short educational
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short educational program for primary care professionals including a decision support tool and monthly feedback report.
Trial: 25880498
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of educational interventions for patients and professionals.
Trial: 21325473
Drug: High-soy diet
RxNorm normalized name: soy acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-soy diet (2 servings/day: 177 mL soy milk, 126 g tofu, or 23 g soy nuts) for 6 months
Trial: 19919978
Drug: Fixed-dose combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination isosorbide-dinitrate/hydralazine
Trial: 15090059
Drug: Concurrent tone
RxNorm normalized name: docusate
DrugBank: Docusate (DB11089)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent tone of constant intensity delivered dichotically at the contralateral ear (left)
Trial: 2807359
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose Metoprolol (0.36 to 0.65 mg/kg/day)
Trial: 2807359
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose Metoprolol (0.66 to 0.99 mg/kg/day)
Trial: 2807359
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose Metoprolol (1 to 1.81 mg/kg/day)
Trial: 2807359
Drug: Comparison with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison with Goteberg Metoprolol trial and MIAMI trials (200 mg/day)
Trial: 1103934
Drug: 2% miconazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% miconazole in cream and powder base
Trial: 31926893
Drug: Erbium glass,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erbium glass, 1540 nm laser treatment 24 hours before surgery
Trial: 12855928
Drug: 100 mg/d
RxNorm normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/d spironolactone (DIUR)